Robotic Assistance Devices, Inc. (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc., is proud to announce the launch of AVA™ (Autonomous Verified Access) Gen 4, ...

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ...

Robotic Assistance Devices, Inc. (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. continues to expand its presence in the healthcare industry, ...

Hospitals deploying RAD's security solutions are reporting significant improvements in safety and efficiency. These ...

Edward Chung; Vice President - Investor Relations; Bio Rad Laboratories Inc. Unidentified Company Representative. Roop Lakkaraju; Chief Financial Officer, Executive ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst ...

ROAMEO Gen 4 provides a powerful ... As more hospitals move toward intelligent automation for security, RAD continues to expand its presence in the healthcare sector, delivering technology ...

C-Rad AB (FRA:24C) reports strong profitability and APAC expansion amid macroeconomic headwinds and order cancellations.

This is an important and solid study that examines the role of TFAM, a protein that helps maintain mtDNA, in mtDNA mutator mice. The authors have demonstrated that TFAM's counteractive role in mtDNA ...

Bio-Rad continues to expand the digital PCR platform’s penetration ... Bio-Rad’s 2024 earnings per share (EPS) has increased 0.4% to $10.33 in the past 30 days. The Zacks Consensus Estimate ...